





Defining the Future of Radiopharma

JP Morgan 43rd Annual Healthcare Conference, 12-16 January 2025

NASDAQ: TLX | ASX: TLX



Disclaimer

This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website.

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this presentation are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this presentation, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in this presentation.

This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Telix’s actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

This presentation also contains estimates and other statistical data made by independent parties and by Telix relating to market size and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of Telix’s future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.

Telix’s lead imaging product, gallium-68 (⁶⁸Ga) gozetotide injection (also known as ⁶⁸Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. No other Telix product has received a marketing authorization in any jurisdiction.

This presentation has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix®, Gozellix®, Pixclara®, Scintimun® and Zircaix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Gozellix, Pixclara and Zircaix brand names subject to final regulatory approval.



Company Overview




Theranostics are the future of oncology

A powerful way to tackle cancer

“See It,
Treat It”

- Highly-targeted
- Patient-centric
- Personalized

TLX101 Therapy: Patient with glioblastoma, TLX101-CDx PET imaging demonstrating response at 4 months¹




Baseline T=0
TLX101-CDx
(Pixclara®³,
[¹⁸F] FET) PET⁴

Treatment with TLX101
T=9 weeks
T= 13 weeks
Overlay post therapy
SPECT⁵

Follow up
T=19 weeks
TLX101-CDx
PET

TLX400 therapy: Patient with breast cancer demonstrating significant tumor mass reduction²



Baseline T=0
TLX400-CDx
FAP-targeted PET

TLX400 Treatment
(SPECT imaging)

Post-Tx (4 cycles)
TLX400-CDx
FAP-targeted PET



1. TLX101 Compassionate Use program. Case study presented at EANM October 2024. Credit N. Tolboom, UMC Utrecht.
2. ¹⁷⁷Lu-based, FAP-targeted therapeutic candidate.
3. Brand name subject to final regulatory approval.

4. Positron emission tomography.
5. Single photon emission computed tomography.

Patient representative scans – individual results may vary.

Telix: A unique company


We are leading the theranostic medicine modality

The **only** pure-play radiopharmaceutical company with:

Strong commercial record
FY2024 revenue: US\$517M –
55% increase YOY¹



Deep theranostic pipeline –
multiple near-term catalysts
plus next-generation assets



**Manufacturing, isotope and
distribution partnerships
delivering to patients**




Patient representative scans – individual results may vary.

1. FY2024 revenues are unaudited, preliminary and based on management's estimate as of the date of this presentation and are subject to completion of the Company's financial closing procedures. Refer to ASX and SEC announcement in respect of Telix's Q4 2024 revenue and business update dated 13 January 2025 for further details, including reported AUD figures.

Commercial performance

Full year guidance - beat



FY2024 Total revenue (unaudited)¹

US\$517M

Up 55% from US\$333M in FY2023

Guidance FY2024: US\$490 million to US\$510 million



1. FY2024 revenues are unaudited, preliminary and based on management's estimate as of the date of this presentation and are subject to completion of the Company's financial closing procedures. Refer to ASX and SEC announcement in respect of Telix's Q4 2024 revenue and business update dated 13 January 2025 for further details, including reported AUD figures.

2025 Roadmap


Clear strategy, multiple near-term value drivers



Commercial portfolio and geographic expansion


Preparing for multi-product launches in 2025

U.S.: Zircaix®¹ BLA submitted; PDUFA dates for Gozellix®² and Pixclara®³
Global expansion of Illuccix®



Late-stage therapeutic pipeline

Focus on urology, neuro-oncology and musculoskeletal oncology, **targeting three assets in pivotal trials in 2025**



Advancing “next generation” radiopharmaceuticals

Harnessing the potential of **alpha emitting isotopes**, and further establishing **in-house discovery platform**



Patient confidence from world-class manufacturing


Supply chain, manufacturing capacity and advanced production technologies to **underpin our growth and meet global demand**



1. Zircaix®: TLX250-CDx for kidney cancer imaging, brand name subject to final regulatory approval.
2. Gozellix®: TLX007-CDx for prostate cancer imaging, brand name subject to final regulatory approval.
3. Pixclara®: TLX101-CDx for glioma imaging, brand name subject to final regulatory approval.


The immediate opportunity

High unmet medical need, significant value creation



Gozellix, Pixclara and Zircaix brand names subject to final regulatory approval.
 1. Management estimate for 2025 based on latest incidence and pricing models.

Therapeutics Platform



Therapeutics strategy

Multiple near-term catalysts and next-generation assets

Progress multiple late-stage therapeutic assets to pivotal trials

Prostate cancer

β

TLX591

Potential first radiolabelled antibody (rADC)² in 1L/2L mCRPC³

β

TLX090

Novel osteoblastic bone metastases palliation

RCC, other CAIX¹-expressing tumors

β

TLX250

Potential first-in-class radiopharmaceutical (rADC) in metastatic ccRCC⁴

Brain, other rare cancers

β

TLX101

Potential first systemic radiotherapy in glioblastoma

Advance next-generation radiopharma platform

α

TLX592

Follow-on opportunity with Actinium-225 labelled antibody. Alternate clinical settings with unmet need

α

TLX252

Pan-cancer target enables expansion to other CAIX-expressing tumors with alpha-emitter

α

TLX102

Follow-on opportunity with Astatine-211 alpha emitter

α

TLX300






First-in-class targeted radiation therapy in soft-tissue sarcoma



1. Carbonic anhydrase IX.
2. Radio antibody-drug conjugate.
3. Metastatic castrate resistant prostate cancer.
4. Clear cell renal cell carcinoma.

Late-stage pipeline

Clinically-validated programs, targeting three assets in pivotal trials in 2025

	Targeting agent	Isotope	Phase 1	Phase 2	Phase 3	Catalysts
Prostate PSMA ¹	Antibody	¹⁷⁷ Lu				ProstACT GLOBAL Ph3 trial in progress, Part 1 readout H1 2025
Kidney + other CAIX	Antibody	¹⁷⁷ Lu				STARLITE trials: First-in-class rADC, moving into pivotal trial in ccRCC Indication expansion - feasibility
Brain LAT ²	Small molecule	¹³¹ I				IPAX-Linz trial complete, pivotal trial design in consultation with FDA
Musculo-skeletal	Antibody	⁹⁰ Y				Preparing IND ⁴ for Ph2 trial
	Small molecule	¹⁵³ Sm				Finalizing Ph2 study design/protocol based on FDA guidance



1. Prostate-specific membrane antigen.
2. L-type amino acid transporter.

3. Cluster of differentiation 66.
4. Investigational new drug (application).

Early-stage pipeline

The “next generation” of products

	Targeting agent	Isotope	R&D	Pre-clinical	Clinical (Ph 0/1)
Prostate PSMA	Antibody	²²⁵ Ac (alpha)	TLX592 (²²⁵ Ac-RADmAb®)		
Kidney + other CAIX	Antibody	²²⁵ Ac (alpha)	TLX252 (²²⁵ Ac-girentuximab)		
Brain LAT	Small molecule	²¹¹ At (alpha)	TLX102 (²¹¹ At-APA)		
Sarcoma PDGFRα1	Antibody	Undisclosed	TLX300 (-olaratumab)		
Bladder FAP²	Small molecule	Undisclosed	TLX400 (New in-license)		



1. Platelet derived growth factor receptor alpha.
2. Fibroblast activation protein.

TLX591: A highly differentiated approach to PSMA therapy

Potential to overcome limitations of small molecule approach



SURVIVAL


Promising overall survival demonstrated in early studies, median OS 42.3 months¹

DOSING

Simple 2-dose regimen
Lower cumulative radiation exposure (152 mCi v 1200 mCi)

QoL²

Limited off target side effects: renal toxicity, dry mouth, dry eye, ganglia irritation. Predictable hematological response



Key near-term catalyst

ProstACT GLOBAL Phase 3 study dosing patients. Interim readout H1 2025 – Part 1 combination safety and dosimetry




1. Tagawa, et al. *Cancer*. 2019 (Open label, single-arm Phase 1/2 clinical trial in 17 patients with advanced mCRPC).
2. Quality of life.
3. ProstACT SELECT data on file.

Patient representative scans - individual results may vary.

TLX250: Targeting ccRCC, pan-cancer potential

Positioned to be first CAIX-targeting rADC to market

TLX250-CDx detection of CAIX expressing tumors



- Promising target expressed in **>90% of ccRCC** (most common kidney cancer) and range of solid tumors²
- Validated ability to image CAIX with girentuximab targeting agent, use of extensively studied Lutetium-177 payload de-risks clinical program³
- Demonstrated durable disease control in **2 trials across 37 patients** with a manageable safety profile^{4,5}
- RCC as 7th most common cancer⁶, **initial opportunity in late-line disease with high unmet need**




1. Computed tomography.
2. Pastorekova S and Gillies RJ. *Cancer Metastasis Rev.* 2019.
3. Shuch et al. *Lancet Oncology.* 2024.


4. Stillbroer et al. *European Urology.* 2013.
5. Muselaers et al. *European Urology.* 2015.
6. Alves WEFM et al. *BMC Cancer.* 2019.

TLX101: Impacting glioblastoma

A compelling direction for an unmet medical need



TLX101 scan showing glioblastoma uptake¹



Overlay post therapy SPECT/MRI²

- **Patient need:** Glioblastoma currently has poor outcomes with a median overall survival of 12-15 months³, 5-year survival of 4.7%
- TLX101 granted orphan drug designation in the U.S. and EU for the treatment of glioma
- **Companion diagnostic:** Pixclara⁴ (TLX101-CDx) submitted for NDA⁵ in 2024, granted Priority Review with a PDUFA⁶ goal date of 26 April 2025
- **Clinical outcomes:** IPAX-1 demonstrated promising efficacy: median overall survival of 23 months from initial diagnosis⁷

Two key near-term catalysts

IPAX-2: Phase 1 study in front-line setting

In progress, positive engagement with FDA on pivotal trial design, planned commencement 2025

IPAX-L: Phase 2 investigator-led study in recurrent setting

Completed enrolment, data expected in H1 2025



Patient representative scan - individual results may vary.

1. Credit: UMC Utrecht Compassionate Use Program.
2. Magnetic resonance imaging.

3. Ostrom et al. *Neuro Oncol.* 2018.

4. Brand name subject to final regulatory approval.
5. New drug application.


6. Prescription Drug User Fee Act.

7. Pichler et al. *Neuro-oncology Advances.* 2024.

TLX090: Next generation for metastatic cancer

Pain management and palliative treatment of osteoblastic bone metastases

SPECT/CT scan of metastatic prostate cancer patient showing targeted uptake of TLX090



- **Patient need:** Relief from pain due to bony (osteoblastic) metastases needs new, cost-effective solutions. Current standard of care relies heavily on opioids, creating compliance issues, and offering low quality of life for patients
- Most prostate cancer patients and 20% of breast cancer patients progress with bony lesions, with considerable pain¹
- **Benefits:** Single dose of TLX090 potentially offers up to four months of pain relief and quality of life. Repeat dosing potential
- **Clinical outcomes:** Phase 1 trial demonstrated highly targeted uptake in bone tumors, favorable safety profile and efficacy in reducing bone pain

Two key near-term catalysts

Dec 2024 Type B Pre-IND Meeting

Received clear guidance on planned study design and pathway to pivotal trial

Finalizing study design/protocol based on FDA guidance

Recruitment expected to commence 2025





Patient representative scans - individual results may vary.

1. Huang, J., et al., (2020). Incidence Of Patients with Bone Metastases At Diagnosis Of Solid Tumors In Adults: A Large Population-Based Study. Doi: 10.21037/atm.2020.03.55

TLX400: Fibroblast activation protein (FAP) targeting

Next-generation asset, pan-cancer potential

FAP therapy (TLX400) in RAI-R¹-thyroid cancer²



- **Fibroblast activation protein (FAP)** is one of the targets with the most potential in nuclear medicine – expressed in over 90% of epithelial cancers³
- **Next-generation assets** have potential for imaging, and both alpha and beta therapy applications
- **Demonstrated safety and efficacy** profile with extensive pre-clinical and clinical validation
- **Developed by** renowned radiochemist Professor Frank Roesch and team
- **Bolsters Telix pipeline** with a pan-cancer program complementing our CAIX portfolio
- **Initial development program** to focus on bladder cancer, builds out existing urology franchise




Patient representative scans - individual results may vary.

1. Radioactive iodine-refractory thyroid cancer.
2. Adapted from Sanjana Ballal, SNMMI Presentation 2023.

3. Rettig et al. *Proc Natl Acad Sci USA*. 1988.

Precision Medicine



Precision medicine strategy

Expanding Telix's industry-leading precision medicine franchise

Multiple commercial products

New product launches¹

- Preparation for U.S. launches in 2025 for
- Gozellix® (prostate)
 - Pixclara® (GBM²)
 - Zircaix® (renal)

Global expansion and patient reach

- Illuccix® approvals expected in EU, UK, Brazil in 2025
- Illuccix Phase 3 bridging studies - China and Japan

Grow market share

- Continued focus on innovation and customer service to drive increased market share for each product and indication

Clinical leadership in precision medicine

- Label expansion and multi-product lifecycle development for PSMA imaging
- Label expansion studies for kidney and brain²

- Regulatory filings to support global rollout of Gozellix, Pixclara and Zircaix
- Supporting multiple third-party clinical trials globally

- Partner to leverage AI³ and technology for enhanced imaging
- Effective lifecycle management across multiple products



Gozellix, Pixclara and Zircaix brand names subject to final regulatory approval.

1. Subject to regulatory approval.
2. Glioblastoma.
3. Artificial intelligence.

Global product expansion

Transition to a global, multi-product commercial product portfolio is underway

PSMA Prostate

- Gozellix: follow-on PSMA product, PDUFA goal date 24 March 2025
- Illuccix: EU decision date mid-January, UK and Brazil decisions expected H1 2025
- China: Illuccix Phase 3 bridging study complete



CAIX Kidney

- Zircaix BLA filed with the FDA December 2024¹
- Expanded access program at >30 sites globally
- ZIRCON peer review data published in *Lancet Oncology*²
- Included in EAU guidelines³ as an emerging technology



LAT Brain

- NDA accepted by FDA; granted priority review, PDUFA goal date 26 April 2025
- First PET-based response assessment criteria for diffuse gliomas issued by RANO⁴
- Expanded access program launched in the U.S.



Gozellix, Pixclara and Zircaix brand names subject to final regulatory approval.

1. Intended to remediate a filing issue with the initial Biologics License Application (BLA) submission from June 2024. See Telix ASX disclosures 31 July 2024 and 30 December 2024.


2. Shuch et al. *Lancet Oncol.* 2024.

3. European Association of Urology Guidelines on Renal Cell Carcinoma (April 2024).

4. Albert et al. *Lancet Oncol.* 2024. Response assessment in neuro-oncology criteria.

Indication expansion to grow the opportunity

Driving clinical utility and differentiation across the patient journey in prostate cancer



1. Radioligand therapy.
2. Hepatocellular carcinoma.
3. Androgen deprivation therapy.
4. Prostate-specific antigen.

● Current indication

● Expanded indication

● Other disease indication

Sustained leadership in prostate cancer imaging

PSMA targeting is solved, technology will further unleash the power of imaging

Telix PSMA

Enhancing imaging with AI

Proprietary tools and clinical decision support software. Telix + SubtlePET, a virtual upgrade for any PET scanner

Reach access “deserts”

Gozellix® delivers PSMA imaging to the last mile, transforming access

Grow the market

Label-expanding PSMA “digital biopsy” study commencing 2025

Investment in innovation


Multi-product lifecycle management

International expansion

Committed to global access of our best-in-class product

New camera technology

Augments sensitivity to enable PSMA detection at very low PSA levels¹. Close cooperation with scanner OEMs²



Gozellix brand name subject to final regulatory approval.

1. Hicks et al. *European Urology Open Science*, 2025.

2. Original Equipment Manufacturers.

Total-body Illuccix PET-CT. Patient representative scan - individual results may vary. Credit: BAMF Health.

Zircaix®: “Practice-changing” solution for renal imaging

ZIRCON imaging data validates target in ccRCC^{1,2}

- **Sensitivity of 86% and specificity of 87%**, PPV³ of 93% in patients with cT1 indeterminate renal mass (≤ 7 cm)
- **High diagnostic performance** for detection and characterization of small and very small renal masses
- **Primary and secondary endpoints met by all three readers**
- **No safety concerns**
- **Non-invasive technique** may be especially beneficial to those at risk of complications from a surgical renal mass biopsy



TLX250-CDx

“has a favorable safety profile and is a highly accurate, non-invasive imaging modality for the detection and characterization of ccRCC, which has the potential to be practice changing¹.”



Zircaix brand name subject to final regulatory approval.

1. Shuch et al. *Lancet Oncol.* 2024.
2. Telix ASX disclosures 7 November 2022.
3. Positive predictive value.


THE LANCET Oncology

[⁸⁹Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial

Brian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, Michael A Morris, Viraj Master, Andrew M Scott, Charles van Praet, Clement Bailly, Bolent Onal, Tamer Aksoy, Robin Merks, David M Schuster, Sze Ting Lee, Neeta Pandit-Taskar, Alice C Fan, Phillip Allman, Karl Schmidt, Libuse Tauchmanova, Michael Wheatcroft, Christian Behrenbruch, Colin RW Hayward, Peter Mulders

Summary

Background With limitations of conventional imaging and biopsy, accurate, non-invasive techniques to detect clear-cell renal cell carcinoma in patients with renal masses remain an unmet need. ⁸⁹Zr-labelled monoclonal antibody [⁸⁹Zr]Zr-girentuximab has high affinity for carbonic anhydrase 9, a tumour antigen highly expressed in clear-cell renal cell carcinoma. We aimed to evaluate [⁸⁹Zr]Zr-girentuximab PET-CT imaging for detection and characterisation of clear-cell renal cell carcinoma.





Pixclara®: Preparation for 2025 commercial launch

Unmet need for delineating progressive disease from treatment-induced changes

- **U.S. total addressable market:** 95,000+ scans across multiple clinical indications; market value US\$475-665M¹
- **Initial indication:** Characterizing recurrent glioma or treatment-induced change. Patient selection tool for TLX101 therapeutic
- A potentially valuable tool for management of progression/ treatment monitoring
- **Orphan drug designation**, potential to meet major unmet need
- **Widely used in Europe and recommended** in the EANM / EANO / RANO / SNMMI guidelines for PET imaging of gliomas¹
- **First PET-based response assessment criteria** for diffuse gliomas issued by RANO in January 2024²

**NDA submitted to FDA in 2024,
granted Priority Review and provided
a PDUFA goal date of 26 April 2025**

ROC³ analysis of 80 patients with grade 3/4 glioma or brain metastases demonstrated superior accuracy of ¹⁸F-FET PET compared with MRI⁴



Patient representative scans - individual results may vary.



Pixclara brand name subject to final regulatory approval.

1. Management estimate based on latest incidence (American Cancer Society, ACS data) and pricing models.
2. Verger et al. *EJNMMI*. 2025.

3. Albert et al. *Lancet Oncol*. 2024.

4. Receiver operating characteristic.
5. Veronesi et al. *J Nucl Med*. 2023.

Telix Manufacturing Solutions



Global manufacturing capability is key to delivery


Ensuring confidence through world-class manufacturing and supply chain capabilities

Our strategy is based on:

Scaling to meet rapid growth and demand


Building partnerships to drive success

Harnessing resources and expertise



Global patient reach

A strategy combining partnerships and owned assets




RLS acquisition subject to completion.
Expected early Q1 2025.


U.S. coverage

Multiple channels ensure patient access and industry leading reliability

Strategic partner pharmacy network



Telix-owned network



More than “bricks and mortar” – talent and expertise

Global reach, international talent pool and an unrivalled R&D platform



 Optimal Tracers

California, U.S.



Vancouver,
Canada



Texas, U.S.



U.S. (Nationwide)



TMS
(Telix Mfg Solutions)
Brussels,
Belgium



RLS acquisition subject to completion.
Expected early Q1 2025.

Delivering in 2025



Multiple drivers of value creation

Foundations in place for rapid and sustainable growth

2025

A transformative year for Telix

Commercial Growth

- Proven track record of delivery
- Preparing to launch multiple products in 2025¹
- Ex-U.S. business expansion

Pipeline Development

- Multiple near-term catalysts
- Key therapeutic assets progressing to pivotal trials
- Advancement of next-generation assets

Ensuring Patient Access

- Industry-leading supply chain, production technology and distribution capabilities
- Valued regional strategic partnerships

Delivering the plan

Catalysts



Commercial portfolio and geographic expansion



Progress late-stage therapeutic pipeline



Advance next generation radiopharmaceuticals



World-class manufacturing

H1 2025

ProstACT GLOBAL (TLX591)
Ph 3 interim readout

TLX592 alpha therapeutic
trial commencement

IPAX-2 and IPAX-Linz (TLX101)
therapy studies readouts

Gozellix¹ & Pixclara¹ FDA
approval decisions (U.S.)

TLX250 program update and
interim data

RLS acquisition completion
(expected early Q1 2025)

ZOLAR (TLX300) patient dosing

TMS Brussels South GMP²
accreditation and “hot” doses

Illuccix Brazil, EU and UK
approval decisions

Illuccix China Ph 3 bridging study
complete

PSMA biopsy expansion study
commencement

Novel biologics platform and Tx
assets transaction completion

H2 2025

Zircaix¹ anticipated FDA approval
decision (U.S.)

SubtlePET + Zircaix¹ (combo) AI
filing and approval decision (U.S.)

Gozellix¹ filing (Aus)

Illuccix Japan Ph3 trial enrolment

TLX101, TLX250 pivotal trials
commencement

TLX252 alpha trial commencement

ZOLAR trial interim readout



1. Brand names subject to regulatory approval
2. Good manufacturing practice.

Contact :

Belinda White
Investor Relations
belinda.white@telixpharma.com




Illustration showing TLX250 binding to carbonic anhydrase IX and internalization